133 related articles for article (PubMed ID: 3103670)
21. Tissue plasminogen activator-induced secretion of type-1 plasminogen activator inhibitor in cultured human fibroblasts.
Reilly TM; Greenplate G; Timmermans PB
Thromb Res; 1989 Sep; 55(5):619-25. PubMed ID: 2510361
[TBL] [Abstract][Full Text] [Related]
22. [Quantification of a specific inhibitor (PAI-1) of tissue-type plasminogen activator (t-PA) in the plasma].
Masson C; Angles-Cano E
Ann Biol Clin (Paris); 1989; 47(5):269-74. PubMed ID: 2500878
[TBL] [Abstract][Full Text] [Related]
23. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
Pannell R; Black J; Gurewich V
J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
[TBL] [Abstract][Full Text] [Related]
24. [Disorders of the liberation of tissue-type plasminogen activator (t-PA) from the venous wall as a cause for recurrent thromboses].
Hach-Wunderle V; Scharrer I
Vasa Suppl; 1993; 39():5-10. PubMed ID: 8322122
[TBL] [Abstract][Full Text] [Related]
25. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium.
Sprengers ED; Verheijen JH; Van Hinsbergh VW; Emeis JJ
Biochim Biophys Acta; 1984 Sep; 801(2):163-70. PubMed ID: 6541058
[TBL] [Abstract][Full Text] [Related]
26. Release of tissue plasminogen activator and its fast-acting inhibitor in defective fibrinolysis.
Pizzo SV; Fuchs HE; Doman KA; Petruska DB; Berger H
Arch Intern Med; 1986 Jan; 146(1):188-91. PubMed ID: 2935105
[TBL] [Abstract][Full Text] [Related]
27. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
Juhan-Vague I; Valadier J; Alessi MC; Aillaud MF; Ansaldi J; Philip-Joet C; Holvoet P; Serradimigni A; Collen D
Thromb Haemost; 1987 Feb; 57(1):67-72. PubMed ID: 3109059
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1.
Booth NA; Walker E; Maughan R; Bennett B
Blood; 1987 Jun; 69(6):1600-4. PubMed ID: 2953396
[TBL] [Abstract][Full Text] [Related]
29. Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
Levi M; Lensing AW; Büller HR; Prandoni P; Dooijewaard G; Cuppini S; ten Cate JW
Thromb Haemost; 1991 Oct; 66(4):426-9. PubMed ID: 1796391
[TBL] [Abstract][Full Text] [Related]
30. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
31. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components.
Colucci M; Paramo JA; Stassen JM; Collen D
J Clin Invest; 1986 Jul; 78(1):138-44. PubMed ID: 3088040
[TBL] [Abstract][Full Text] [Related]
32. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
33. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
34. Sensitive and direct assays for functionally active plasminogen activators (tissue-type and urokinase-type) in plasma.
Mahmoud-Alexandroni M; Heath AB; Gaffney PJ
Am J Clin Pathol; 1989 Sep; 92(3):308-14. PubMed ID: 2505607
[TBL] [Abstract][Full Text] [Related]
35. Identification of a reversible inhibitor of plasminogen activators in blood plasma.
Kluft C; Jie AF; Sprengers ED; Verheijen JH
FEBS Lett; 1985 Oct; 190(2):315-8. PubMed ID: 3930295
[TBL] [Abstract][Full Text] [Related]
36. Tissue plasminogen activator inhibitor in human plasma: development of a functional assay system and demonstration of a correlating Mr = 50,000 antiactivator.
Korninger C; Wagner O; Binder BR
J Lab Clin Med; 1985 Jun; 105(6):718-24. PubMed ID: 3923146
[TBL] [Abstract][Full Text] [Related]
37. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.
Thorsen S; Philips M; Selmer J; Lecander I; Astedt B
Eur J Biochem; 1988 Jul; 175(1):33-9. PubMed ID: 3136015
[TBL] [Abstract][Full Text] [Related]
38. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.
Schleef RR; Higgins DL; Pillemer E; Levitt LJ
J Clin Invest; 1989 May; 83(5):1747-52. PubMed ID: 2496147
[TBL] [Abstract][Full Text] [Related]
39. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.
Hamsten A; Wiman B; de Faire U; Blombäck M
N Engl J Med; 1985 Dec; 313(25):1557-63. PubMed ID: 3934538
[TBL] [Abstract][Full Text] [Related]
40. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
